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Abstract
Background: Despite the availability of guidelines for the specific treatment of hereditary angioedema (HAE) attacks,
HAE morbidity and mortality rates remain substantial. HAE attacks are a major medical issue requiring specific treatment
as well as a considerable socio-economic burden. We report a protocol designed to test whether a dedicated call centre
is more effective than usual practice in the management of patients experiencing an HAE attack.
Methods/design: This prospective, cluster-randomised, single-blind, parallel-group, multicentre trial evaluates the
morbidity and consequent socio-economic costs of the management of patients experiencing an HAE attack by a
dedicated call centre as compared to usual practice. The trial aims to recruit 200 patients. Patients in the intervention
arm are provided with an SOS-HAE card with the call centre’s freephone number that they can access in the case of an
attack. The centre’s mission is to provide recommended expert advice on early home treatment. The centre can route
the call to a local emergency medical service with competency in HAE management or even arrange for the drugs
needed for the specific treatment of an HAE attack to be sent to the emergency department of the local hospital. The
primary outcome measure is the number of hospital admissions for an HAE attack. Each patient will be followed up
every 2 months for 2 years. The study has been approved by the ethics committee (Comité de Protection des Personnes
d’Ile de France 10; registration number: 2012-A00044-39; date of approval: 19 January 2012).
Discussion: The SOS-HAE protocol has been designed to address the handling of attacks experienced by patients with
HAE in the home. The proposed trial will determine whether the setting up of a dedicated call centre is more effective
than usual practice in terms of reducing morbidity as given by the numbers of hospital admissions. The results are also
anticipated to have important implications in terms of socio-economic costs for both healthcare services and patients.
Trial registration: ClinicalTrials.gov NCT01679912.
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Background
Hereditary angioedema (HAE) is a rare disease. Worldwide
prevalence ranges from 1/50,000 to 1/100,000 [1]. The form
exhibiting C1 inhibitor (C1-INH) deficiency is an auto-
somal dominant disorder, although 25 % of cases are due to
a spontaneous mutation in individuals with no family his-
tory of the disease [2, 3]. Patients with C1-INH deficiency
may have type I or type II HAE [2, 3]. Patients with a family
history of angioedema but with normal C1-INH levels may
have a mutation of the gene encoding human coagulation
factor XII (FXII-HAE) [2].
HAE attacks are characterised by recurrent subcutane-
ous swelling without itching lasting 48 to 72 hours [3, 4].
By far the most common sites of attacks are the extrem-
ities and abdomen, each accounting for nearly half of all
attacks [5]. Abdominal attacks can cause severe pain and
third-space fluid accumulation with resultant hypotension
[5, 6]. Moreover, more than half of all HAE patients ex-
perience at least one laryngeal attack during their lifetime
with the associated risk of asphyxiation [7]. Despite the
availability of guidelines on specific treatments for HAE
attacks, morbidity and mortality rates remain substantial
[2, 3, 8].
The management of patients with HAE is shifting to-
wards self-treatment of attacks at home with fewer visits to
the hospital emergency department (ED) and fewer admis-
sions [9, 10]. Even so, in a recent retrospective study of 193
HAE patients with 8 attacks/patient/year, approximately
11 % of patients visited the ED [11]. Moreover, according to
a prospective observational study including 29 HAE pa-
tients, laryngeal and facial edemas are independent risk
factors associated with hospital admission, and this is not
avoided by early ED arrival [12]. A prospective study on the
impact of measures, in particular specific home treatments,
that might shorten the time from attack onset to first con-
tact with a healthcare professional is required [12].
HAE attacks are not only an important medical issue
but also a socio-economic issue [13]. Costs and hospital
stays increase with attack severity [13]. A randomised
study evaluating a telephone care-management strategy
versus usual practice reported a significant decrease of
average medical costs and hospital admissions in the
telephone-coached group [14]. The aim of our multicen-
tre, cluster-randomised, controlled trial is to determine
whether a central dedicated call centre for HAE attacks that
provides guidelines-based, standardised advice on early
treatment would reduce the number of hospital admissions




The SOS-HAE trial is a prospective single-blind, two-arm,
cluster-randomised, multicentre trial for patients with HAE
attending a reference centre for bradykinin-mediated angio-
edema. Because the prevalence of HAE is low, the study
will include only adult patients with an HAE diagnosis
already confirmed by a specialist on the basis of patient
history, functional and antigenic C1-INH levels and genetic
data. Each investigator will select eligible patients (those
with type I HAE, type II HAE or FXII-HAE) from amongst
his/her reference centre’s customary patient population.
Ethical aspects
The SOS-HAE study protocol and patient information
sheets have been approved by the ethics committee and
by the competent French authorities (Comité de Protection
des Personnes d’Ile de France 10; Hôpital Robert Ballanger;
registration number: 2012-A00044-39; date of approval:
19 January 2012).
Patients are informed orally and in writing (SOS-HAE
information sheet) by the investigator and can refuse to
participate. Written informed consent is required by French
law, as the standard of care does not apply to both study
arms.
Participating centers
Eight French reference centres for bradykinin-mediated
angioedema are participating in the trial. The centres were
accredited in 2006 by the French Ministry of Health. Their
mission is to improve access to diagnosis and therapy for
patients with HAE. All eight centres have medical and
paramedical teams with experience in the field of HAE, all
implement a therapeutic education programme based on
guidelines for systematic treatment of severe attacks and
for prophylaxis of recurrent attacks, and all offer nurse-led
sessions on self-administration of specific therapy for an
attack [2, 3, 8, 15].
The freephone call centre (0800 111 001) is hosted by
the French emergency medical service (EMS) of a Paris
suburb (SAMU 93) which has the logistics capabilities
needed to provide 24/7/365 expert medical advice over
the telephone [16]. SAMU 93 has promoted appropriate
care of HAE attacks by (1) posting placards in SAMU 93
to enhance awareness and (2) providing their emergency
physicians with instruction sheets on recommended emer-
gency management of HAE attacks and prophylaxis of
recurrence [2].
In France, each local EMS is equipped with one or
more mobile intensive care units (MICUs), which include
a senior emergency physician, a nurse and an ambulance
driver. MICUs provide rescue techniques and medical ad-
vice, known as advanced life support, throughout France
[16]. The local EMS facilities of each participating refer-
ence centre have the required logistics capabilities for
storage and around-the-clock delivery of appropriate spe-
cific agents (plasma-derived C1-INH and icatibant) to
patients or healthcare organisations [17]. If the case is life-
Javaud et al. Trials  (2016) 17:225 Page 2 of 7
threatening, SOS-HAE will immediately contact SAMU
headquarters.
Study population
Eligible patients are adults (≥18 years) with HAE at one of
the eight participating reference centres. Inclusion criteria
are a documented diagnosis of HAE (type I, II or FXII-
HAE) and signed informed consent. Exclusion criteria are
pregnancy, recent history (≤1 month) of myocardial infarc-
tion or ischemic stroke and allergy to icatibant or plasma-
derived C1-INH.
Withdrawal of the study: withdrawal of consent
follow-up.
Randomisation
The randomised units are the reference centres (clusters)
with randomisation stratified according to the number of
eligible HAE patients by reference centre. Using permuted
blocks of 4, we randomly assigned reference centres (not
patients) to the intervention or to usual practice (1:1 ratio).
A modified version of Zelen’s method involving a two-
step informed consent process was used for randomisation
and inclusion [18]. Eligible patients were first invited to
participate in a cohort study but without being informed of
the nature of the study arms. Patients who agreed to par-
ticipate in the study signed the first consent form. This was
followed by verification of eligibility (compliance with inclu-
sion/exclusion criteria) and centre randomisation. The pa-
tients in each centre were then offered inclusion in the arm
assigned to their centre but without being informed of the
nature of the other arm. Patients who agreed to be included
signed the second consent form. The patient inclusion day
is study day zero (D0).
Study arms
The study protocol and randomisation arms are described
in Fig. 1. The methodical management strategy of patients
with HAE experiencing an HAE attack (SOS-HAE) was
conceptualised after discussions of inclusion criteria and
follow-up with a specialist in HAE. The protocol assesses
the impact of the implementation of this strategy on num-
ber of hospital admissions in a group of patients rather
than the actual efficacy of the treatment administered
(Fig. 2).
Intervention arm
All patients in the intervention arm are given an SOS-
HAE card indicating what to do in the case of an attack:
“On attack onset and before taking any drugs, call the
freephone number 0800 111 001”. The physicians receiving
the call at the call centre (open 24/7/365) have received
special training as well as instruction sheets on emergency
HAE management according to attack severity (Table 1).
They can prescribe home treatment or route the call to a
local EMS team with competency in HAE management.
They can also make arrangements for specific drugs to be
sent to the ED of the patient’s local hospital.
Usual practice arm
No changes are made to usual practice treatment, and
patients are not given the SOS-HAE card.
Data collection and follow-up
Medical data
HAE specialists and emergency physicians collect stan-
dardised clinical data including those presented in the
Fig. 1 Study design
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most recent Hereditary Angioedema International Working
Group (HAWK) guidelines [2]:
– On day zero (D0): Patient sex, age, type of HAE (type
I, II or FXII-HAE), time since diagnosis, personal
history of angioedema (ED visits during previous year,
admissions to intensive care unit (ICU) and history of
intubation and tracheotomy), ongoing long-term
treatment and number of relatives with HAE
– At each attack and every 2 months for 2 years:
Number of attacks and, for each attack: possible trigger
of attack, day and time of onset of symptoms, day and
time of call to SOS-HAE centre, edema site, home
therapy (self-administered or caregiver) or hospital
treatment, time treatment started and course of attack
(onset of symptom relief and time of symptom
resolution)
– Number of admissions/patient/year over 2 years,
duration of admissions, number of admissions to
ICU/patient/year over 2 years, number of ED visits/
patient/year over 2 years, number of intubations,
number of interventions by EMS and mortality
Health economics data
Call centre costs include freephone, training of EMS
personnel and answering of calls (time spent and num-
ber of calls).
Patient care costs include consumption of hospital re-
sources (admissions) and out-of-hospital resources (ED
visits or emergency ambulance, drugs to treat attacks
and their administration by physicians or nurses), work-
ing days lost and any remaining costs supported by
patients.
Quality of life
The Short Form Health Survey (SF-36) score is mea-
sured after 1 year and after 2 years of follow-up.
Trial coordination and implementation
Each medical and paramedical team in the eight partici-
pating reference centres and in the SOS-HAE call centre
is trained in protocol implementation and data collection.
The electronic case report form (eCRF) was developed
using CleanWEB™ (a centralised, secure, interactive web
response system edited by Telemedicine Technologies and
accessible from each study centre). In accordance with
Fig. 2 Study flowchart
Table 1 Treatment recommendations
Treatment Recommendations
Vital distress - Immediately and as soon as possible:
- Administer icatibant (Firazyr®): 30 mg subcutaneously or
- plasma-derived C1-INH (Bérinert®): 20 UI/kg
intravenously
- Switch the call to the local SAMU to send French EMS
- Gain control of upper airway
Severe
attacks
- Immediately and as soon as possible:
Laryngeal - Administer icatibant (Firazyr®): 30 mg subcutaneously
or
Facial - plasma-derived C1-INH (Bérinert®): 20 UI/kg
intravenously
Abdominal - If treatments are unavailable at home, switch the call to
the local SAMU to send an ambulance headed towards
a hospital with specific treatments available or being able
to get them by French EMS





- Tranexamic acid: 1 g/6 h except for patients who are
breastfeeding or have thromboembolic pathology
Surveillance
in all cases
Monitoring by phone 30 min, 1 h, 4 h, 12 h and 24 h
after the beginning of the attack
Advice to call back SOS-HAE call centre in case of
secondary worsening
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French law, the eCRF and database were validated by the
CCTIRS (Comité consultatif sur le traitement de l’infor-
mation en matière de recherche dans le domaine de la
Santé - Advisory Committee on Information Processing in
Healthcare Research) and by the CNIL (Commission
Nationale de l’Informatique et des Libertés - French Data
Protection Authority).
Blinding
Physicians and nurses could not be blinded to the interven-
tion given its nature, but patients are blinded to the inter-
vention by Zelen’s method (pre-randomisation consent).
The single-blind procedure is partially counterbalanced by
the objective nature of the primary outcome measure [19].
The analysis will be blinded to group allocation.
Outcome measures
Primary outcome
The primary outcome is the number of admissions for
angioedema attacks per patient per year over a 2-year
period. The number of admissions for angioedema attacks
is measured from the randomisation date until the end of
follow-up or death. For patients discharged alive, informa-
tion on the primary outcome will be collected by phoning
the patients. All admission observation charts are collected
and collated.
Secondary outcomes
Secondary outcomes are the number of admissions for a
cause other than an angioedema attack per year over a 2-
year period, mortality from an angioedema attack, mortality
from another cause, number of ICU admissions per year,
number of ED admissions per year, number of hospital
stays, number of intubations per year, number of interven-
tions by EMS, number of working days lost and their dur-
ation, costs of patient care and SF-36 score.
Definitions
An admission is defined as a hospital stay >12 hours as
an inpatient. An ED visit is defined as a consultation in
the ED without admission (stay ≤24 hours).
Sample size calculation
The aim of this study is to demonstrate a difference in
outcome between a methodical management strategy and
usual practice. Our primary hypothesis is that an SOS-
HAE call centre might benefit patients suffering from an
angioedema attack. The sample size calculation is based
on the primary outcome, i.e. on the number of admissions
for angioedema attacks.
A recent study involving 193 patients with HAE in
France reported a rate of approximately 8 attacks/year/
patient with approximately 11 % of patients coming to
the ED or being admitted to hospital (i.e. an estimated
88 % per year). We hypothesise that implementation of
the SOS-HAE call centre management strategy should
reduce this rate by 20 %, resulting in a rate of 68 % of
ED visits or admissions per year over a 2-year period. If
we consider the design effect due to cluster randomisa-
tion as relatively low (1.4), the estimated required sam-
ple size is 100 patients/arm for 85 % power and a 5 %
alpha risk (two-sided comparison).
Statistical analysis
Descriptive analyses will provide the following informa-
tion for each continuous variable: mean value, standard
deviation, 95 % confidence interval (CI), minimum, first
quartile, median, third quartile and maximum and num-
ber of missing observations. Categorical variables will be
expressed as numbers and percentages.
Analysis of primary outcome
The number of admissions for angioedema attacks will
be analysed in the intent-to-treat population.
Because some patients may be blood relatives and be-
cause data from within the same family are not independ-
ent, the analysis will use generalised mixed models with the
family included in the model as a random effect, the strat-
egy as a fixed effect and with a binomial distribution of the
variable of interest.
All tests will be two-sided.
Analysis of secondary outcomes
Secondary outcomes will be analysed using a mixed
model ANOVA. The family will be introduced into the
model as a random effect. All tests will be two-sided.
Number of admissions for a cause other than an angio-
edema attack per year for 2-year-period, mortality from an
angioedema attack, mortality from another cause, number
of ICU admissions per year, number of ED admissions per
year, number of hospital stays, number of intubations per
year, number of interventions by EMS, number of working
days lost (and duration), costs (hospital and ambulatory
costs) of patient care and SF-36 will all be estimated in each
arm for 2 years.
Discussion
Key priority issues in HAE management are reducing mor-
bidity and mortality rates and socio-economic costs [2].
No study has ever been conducted to determine whether a
central dedicated call centre for HAE attacks would reduce
morbidity and the socio-economic impact of the disease.
The indications for the specific treatment of HAE attacks
are well established. Plasma-derived C1INH and icatibant
are the undisputed emergency drugs for life-threatening
cases (laryngeal involvement), abdominal attacks and cases
with facial involvement [2, 3, 20, 21]. Early home treatment
is recommended [2, 15]. HAE patients trained in icatibant
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self-administration can recognise HAE attacks and decide
when to inject [22], thereby avoiding hospital admission
[12]. In an evaluation of the feasibility and efficacy of
plasma-derived C1-INH in 31 patients with HAE, the time
from attack onset to start of treatment was significantly
shorter after than before training in self-injection [23].
Nevertheless, morbidity remains high in these patients. In
one retrospective study, 73 patients (16 %) presented at the
hospital ED with an attack and 59 % were admitted to hos-
pital [13]. In another, 21 patients (11 %) presented at the
hospital ED with an attack [11]. According to a recent
prospective study, most of these patients visited the ED
because they were short of medication or because they
were unaware that emergency treatment could be
self-administered. Our prospective controlled cluster-
randomised trial would enable evaluation of the im-
pact of a measure (dedicated call centre) that might
shorten the time from attack onset to first contact
with a healthcare professional.
HAE is a considerable economic burden both to the
healthcare system and to HAE patients and their families
[13]. Reducing the number of hospital admissions might
help reduce this burden. We hypothesise that the use of a
dedicated call centre providing expert advice for HAE
might significantly reduce the number of admissions (mor-
bidity rate) and thus the socio-economic costs associated
with the disease.
Trial status
Recruitment for the trial was completed in June 2014.
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